추천 제품
Quality Level
분석
≥98% (TLC)
양식
powder
색상
white to off-white
solubility
methanol: ≥50 mg/mL, clear, colorless to yellow
주관자
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES string
C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O
InChI
1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1
InChI key
UQKQUZOIQFOJOI-KJHLASMFSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
Enalapril is an angiotensin-converting enzyme inhibitor. It is used to treat heart failure and high blood pressure.
애플리케이션
Enalapril maleate salt has been used:
- to reduce albumin excretion rate (AER) and glomerular lesions
- to examine the effects of enalapril pre-treatment on myocardial injury
- to investigate its efficacious doses and schedules for mitigation of radiation lung injury
생화학적/생리학적 작용
A long-acting angiotensin-converting enzyme inhibitor.
특징 및 장점
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
이미 열람한 고객
Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice
Kidney International, 90(5), 1045-1055 (2016)
Enalapril
Drugs, 31(3), 198-248 (1986)
PloS one, 17(1), e0261000-e0261000 (2022-01-28)
Diabetic nephropathy is associated with endothelial dysfunction and oxidative stress, in which the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway is impaired. We hypothesize that sGC stimulator Compound 1 can enhance NO signaling, reduce proteinuria in a diabetic
American journal of physiology. Renal physiology, 319(4), F697-F711 (2020-09-01)
Praliciguat, a clinical-stage soluble guanylate cyclase (sGC) stimulator, increases cGMP via the nitric oxide-sGC pathway. Praliciguat has been shown to be renoprotective in rodent models of hypertensive nephropathy and renal fibrosis. In the present study, praliciguat alone and in combination
Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation
International Journal of Molecular Sciences, 38(5), 1463-1473 (2016)
관련 콘텐츠
Discover Bioactive Small Molecules for ADME/Tox
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.